Related Experiment Video
Updated: Jul 16, 2025
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Discovery of a non-covalent ligand for Rpn-13, a therapeutic target for hematological cancers
Cody A Loy1, Christine S Muli1, Eslam M H Ali1
1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, United States.
Abstract:
The ubiquitin-proteasome system serves as the major proteolytic degradation pathway in eukaryotic cells. Many inhibitors that covalently bind to the proteasome's active sites have been developed for hematological cancers, but resistance can arise in patients. To overcome limitations of active-site proteasome inhibitors, we and others have focused on developing ligands that target subunits on the 19S regulatory particle (19S RP). One such 19S RP subunit, Rpn-13, is a ubiquitin receptor required for hematological cancers to rapidly degrade proteins to avoid apoptosis. Reported Rpn-13 inhibitors covalently bind to the Rpn-13's Pru domain and have been effective anti-hematological cancer agents. Here, we describe the discovery of TCL-1, a non-covalent binder to the Pru domain. Optimization of TCL-1's carboxylate group to an ester increases its cytotoxicity in hematological cancer cell lines. Altogether, our data provides a new scaffold for future medicinal chemistry optimization to target Rpn-13 therapeutically.
Insights
Researchers discovered TCL-1, a novel non-covalent inhibitor targeting Rpn-13, a key protein in hematological cancers. Ester modification of TCL-1 enhanced its cancer-killing ability, offering a new therapeutic strategy.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- The ubiquitin-proteasome system is crucial for protein degradation in eukaryotic cells.
- Proteasome inhibitors are used for hematological cancers, but drug resistance is a challenge.
- Targeting the 19S regulatory particle (19S RP) offers an alternative strategy to overcome resistance.
Purpose of the Study:
- To discover novel ligands targeting the Rpn-13 subunit of the 19S RP.
- To develop non-covalent inhibitors of Rpn-13 as a new therapeutic approach for hematological cancers.
- To optimize lead compounds for enhanced anti-cancer activity.
Main Methods:
- Identification of TCL-1, a non-covalent binder to the Rpn-13 Pru domain.
- Medicinal chemistry optimization of TCL-1, including modification of its carboxylate group.
- Assessment of cytotoxicity of optimized compounds in hematological cancer cell lines.
Main Results:
- Discovery of TCL-1, a novel non-covalent Rpn-13 inhibitor.
- Optimization of TCL-1 by converting the carboxylate to an ester significantly increased cytotoxicity.
- Demonstrated the potential of TCL-1 derivatives as anti-hematological cancer agents.
Conclusions:
- TCL-1 represents a new chemical scaffold for Rpn-13-targeted therapy.
- Ester-modified TCL-1 derivatives show promising anti-cancer activity.
- This work provides a foundation for developing novel therapeutics against Rpn-13 in hematological malignancies.
Related Concept Videos
02:40Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...